Biodexa Pharmaceuticals Statistics
Total Valuation
BDRX has a market cap or net worth of $3.74 million. The enterprise value is -$1.09 million.
Important Dates
The next estimated earnings date is Tuesday, September 23, 2025, before market open.
| Earnings Date | Sep 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BDRX has 619,523 shares outstanding. The number of shares has increased by 567.32% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 619,523 |
| Shares Change (YoY) | +567.32% |
| Shares Change (QoQ) | +101.93% |
| Owned by Insiders (%) | 0.45% |
| Owned by Institutions (%) | 5.99% |
| Float | 608,275 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.07 |
| P/TBV Ratio | 0.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.63, with a Debt / Equity ratio of 0.04.
| Current Ratio | 3.63 |
| Quick Ratio | 3.63 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -35.82 |
Financial Efficiency
Return on equity (ROE) is -61.77% and return on invested capital (ROIC) is -53.41%.
| Return on Equity (ROE) | -61.77% |
| Return on Assets (ROA) | -39.04% |
| Return on Invested Capital (ROIC) | -53.41% |
| Return on Capital Employed (ROCE) | -72.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$656,254 |
| Employee Count | 13 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -397,315 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.13% in the last 52 weeks. The beta is 0.87, so BDRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | -94.13% |
| 50-Day Moving Average | 7.23 |
| 200-Day Moving Average | 22.19 |
| Relative Strength Index (RSI) | 44.93 |
| Average Volume (20 Days) | 53,819 |
Short Selling Information
| Short Interest | 4,289 |
| Short Previous Month | 9,172 |
| Short % of Shares Out | 0.69% |
| Short % of Float | 0.71% |
| Short Ratio (days to cover) | 0.14 |
Income Statement
| Revenue | n/a |
| Gross Profit | -7.45M |
| Operating Income | -12.32M |
| Pretax Income | -9.56M |
| Net Income | -8.53M |
| EBITDA | -12.16M |
| EBIT | -12.32M |
| Earnings Per Share (EPS) | -$66.58 |
Full Income StatementBalance Sheet
The company has $5.53 million in cash and $686,395 in debt, giving a net cash position of $4.84 million or $7.82 per share.
| Cash & Cash Equivalents | 5.53M |
| Total Debt | 686,395 |
| Net Cash | 4.84M |
| Net Cash Per Share | $7.82 |
| Equity (Book Value) | 15.67M |
| Book Value Per Share | 82.33 |
| Working Capital | 8.92M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.74 million and capital expenditures -$15,071, giving a free cash flow of -$14.63 million.
| Operating Cash Flow | -14.74M |
| Capital Expenditures | -15,071 |
| Free Cash Flow | -14.63M |
| FCF Per Share | -$23.62 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
